10-Q: ENDRA Life Sciences Reports First Quarter 2024 Results, Faces Going Concern Challenges

ENDRA Life Sciences reported a net loss of $2.78 million for the first quarter of 2024 and is facing challenges related to its ability to continue as a going concern.

Summary

• ENDRA Life Sciences reported a net loss of $2.78 million for the first quarter of 2024, compared to a net loss of $2.94 million for the same period in 2023.
• The company's operating expenses totaled $2.78 million, with research and development expenses at $1.04 million, sales and marketing at $0.24 million, and general and administrative expenses at $1.50 million.
• ENDRA had cash of $1.13 million as of March 31, 2024, and an accumulated deficit of $94.7 million.
• The company has not generated any revenue from its TAEUS technology as of March 31, 2024.
• ENDRA is facing challenges related to its ability to continue as a going concern and will require additional financing to fund its operations.
• The company is working towards FDA approval for its TAEUS system and anticipates submitting a new de novo request in the first half of 2025.
• A 5% inventory reserve of $142,733 was recorded due to potential damage and longer sales timeframes.

Sentiment

Score: 3

Explanation: The document indicates significant financial challenges, including a going concern warning, lack of revenue, and a low cash balance. While there are some positive developments, such as the FDA pre-submission meeting, the overall sentiment is negative due to the company's financial instability and the delay in FDA submission.

Positives

• Research and development expenses decreased by $349,788 compared to the same period last year, indicating a shift towards commercialization.
• The company has a scheduled pre-submission meeting with the FDA in the second quarter of 2024, which is a step towards regulatory approval.
• The company has a new At-The-Market Issuance Sales Agreement in place to raise capital.

Negatives

• The company reported a net loss of $2.78 million for the quarter.
• ENDRA has not generated any revenue from its TAEUS technology.
• The company has an accumulated deficit of $94.7 million.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company's cash balance is low at $1.13 million.
• The company identified a material weakness in internal control over financial reporting.
• The company received a notification from Nasdaq for not meeting the minimum bid price requirement.

Risks

• The company has a history of operating losses and will need to raise significant additional capital to continue its business.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company may be forced to delay, reduce, or eliminate operating activities if it cannot raise sufficient capital.
• The company is dependent on obtaining regulatory approvals for its TAEUS technology.
• The company faces risks related to market acceptance of its technology and competition in the industry.
• The company has identified a material weakness in internal control over financial reporting.
• The company's stock price is below the Nasdaq minimum bid price requirement, which could lead to delisting.

Future Outlook

The company anticipates completing the necessary clinical studies by the fourth quarter of 2024 and submitting the new de novo request to the FDA in the first half of 2025. The company will need to raise additional capital to fund operations through the next twelve months.

Management Comments

• Management plans to continue as a going concern include raising additional capital through sales of equity securities and borrowing.
• Management cannot provide any assurances that the Company will be successful in accomplishing any of its plans.

Industry Context

The company is developing technology for non-invasive tissue characterization, which is a growing area in medical diagnostics. The company's focus on non-alcoholic fatty liver disease (NAFLD) aligns with the increasing prevalence of this condition and the need for cost-effective diagnostic tools. The company is competing with established imaging technologies like CT and MRI, as well as other emerging ultrasound technologies.

Comparison to Industry Standards

• The company's lack of revenue is not uncommon for early-stage medical device companies, but the significant accumulated deficit and low cash balance are concerning.
• Compared to companies like Butterfly Network (BFLY) which is also developing portable ultrasound technology, ENDRA is at an earlier stage of commercialization and has not yet generated revenue.
• Other companies in the medical device space, such as Exact Sciences (EXAS) and Guardant Health (GH), have demonstrated the potential for rapid growth in the diagnostics market, but they also require significant capital investment and face regulatory hurdles.
• The company's reliance on external funding is similar to many other pre-revenue medical device companies, but the going concern warning highlights the urgency of securing additional capital.

Corporate Governance

Legal Proceedings

• As of March 31, 2024, there were no legal matters that management believes would have a material effect on the Company's financial position or results of operations.

Related Party Transactions

• The company has a consulting agreement with one of its directors, Alex Tokman.
• The company has a consulting agreement with PatentVest, a subsidiary of MDB Capital Holdings, LLC, where two of the company's directors are affiliated.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and the going concern warning.
• Employees may be impacted by potential delays or reductions in operations.
• Customers may experience delays in the availability of the company's products.
• Suppliers and creditors face increased risk due to the company's financial challenges.

Next Steps

• The company will have a pre-submission meeting with the FDA in the second quarter of 2024.
• The company anticipates completing the necessary clinical studies by the fourth quarter of 2024.
• The company plans to submit a new de novo request to the FDA in the first half of 2025.
• The company will need to raise additional capital to fund operations.

Key Dates

Keywords

TAEUS, Thermo-Acoustic Enhanced Ultrasound, NAFLD, FDA, de novo, financial results, going concern, regulatory approval, medical device, liver disease